We here report a rare case of a patient with IgD-lambda-positive multiple myeloma presenting with FDG-PET/CT negative bone marrow involvement. A 72-year-old man was admitted to our hospital for evaluation of a paravertebral tumor of the chest. Thoracotomy was performed and a histopathological evaluation of resected intrathoracic tumor demonstrated a plasmacytic neoplasma. Initially we thought that this case was a solitary plasmacytoma because there were no positive findings on postoperative FDG-PET/CT. However, bone marrow aspiration study demonstrated massive infiltration of myeloma cells (72%). It is necessary to recognize that IgD-lambda type myeloma cells may not be sufficiently metabolically active to form high uptake on FDG-PET/CT.
Introduction
Multiple myeloma (MM) is the most common malignancy of plasma cells (1) . Immunoglobulin D (IgD) myeloma is a rare type of MM accounting for about 1 2% of myeloma cases overall. IgD myeloma shows several unique features such as poor prognosis and smaller size or absence of serum M-protein. The amount of IgD immunoglobulin is relatively less than that of other types of immunoglobulin (2) , probably because IgD clearance is very fast. Furthermore, extramedullary plasmacytoma is not infrequent, and there may be coexisting amyloidosis and renal failure (3) . On staging examination of MM, F18-fluorodeoxyglucose positron emission tomography (FDG-PET) or FDG-PET combined with CT scanning (FDG-PET/CT) has recently been recommended to obtain an accurate whole-body evaluation of MM patients (4-7). However, to our knowledge, there is no report describing FDG-PET or FDG-PET/CT findings of IgD type MM. The theoretical discrepancy between massive bone marrow involvement of myeloma cells and negative FDG-PET/CT findings in the present case is extremely interesting.
Case Report
A 72-year-old man was admitted to our hospital because of a left paravertebral tumor of the chest that was diagnosed on periodic examination during the clinical course following gastric cancer surgery. Computed tomography (CT) and magnetic resonance image (MRI) of his chest demonstrated a solitary tumor without destruction of the adjacent vertebra and rib (Fig. 1) . He had been healthy until two years earlier Division of Pulmonary Medicine, National Hospital Organization National Kochi Hospital, Japan, Department of Clinical Investigation, National Hospital Organization National Kochi Hospital, Japan, Division of Respiratory Surgery, National Hospital Organization National Kochi Hospital, Japan, Division of Pathology, National Hospital Organization National Kochi Hospital, Japan and Division of Internal Medicine, National Hospital Organization National Kochi Hospital, Japan when he was diagnosed as having gastric cancer and underwent resection of the stomach. Familial history was not contributory. On physical examination, there were no remarkable abnormal findings other than surgical scars on his abdomen. Laboratory tests showed mild anemia (hemoglobin, 10.3 g/dL; normal range 13.5-17.0) and mild renal dysfunction (creatinine, 2.0 mg/dL) without other abnormal findings in blood cell count and biochemical tests (Table 1) . Bronchoscopic examination did not detect any abnormalities suggesting tumor in the pleural cavity. Therefore, thoracotomy was performed and histopathological finding on quick intraoperative inspection indicated plasmacytic neoplasma (Fig. 2) . There was no sign of direct bone invasion by tumor cells. Although FDG-PET/CT scan was performed to identify other intra-and extramedullary involvement of myeloma cells, FDG-PET/CT did not demonstrate any abnormal FDG uptake in his body after surgery on the thoracic tumor, suggesting that this patient had a solitary plasmacytoma (Fig. 3) . Bone X-ray examinations also detected no punched-out lesion. In addition, we could not find a distinct M-spike on serum protein fractionation. However, immunoelectroproteinogram indicated IgD-lambda type M-protein in serum (Fig. 4) and lambda type Bence-Jones protein in serum and urine (data not shown). Serum IgD concentration was 564 mg/dL (normal range: <9.0 mg/dL) with suppression of other serum immunoglobulins. Moreover, iliac bone marrow aspiration study demonstrated massive infiltration of myeloma cells (72%) (Table 1, Fig. 5 ). Therefore, we finally diagnosed this patient as having IgD-lambda type MM. Chromosomal abnormalities of bone marrow cells were not observed. The patient was treated with melphalanprednisolone (MP) and obtained a minimal response (Fig. 6 ). One year after the initiation of MP, his condition remained stable.
Discussion
We first recognized this patient based on MRI findings of a lung or mediastinal tumor, because the patient had no subjective symptoms despite an abnormal shadow on chest imaging. Therefore, we decided to resect the tumor after con- firming that there were no metastatic lesions. Even though serum protein fractionation did not show M-spike, if we had focused on mild anemia, renal dysfunction and slight suppression of immunoglobulin G, A and M, the diagnosis might be established using immuno-electroproteinogram and bone marrow aspiration study without surgery. The most significant advantageous feature of FDG-PET/ CT is the ability to distinguish active myeloma from monoclonal gammopathy of undetermined significance (MGUS) or smoldering disease (5) . According to the criteria for the classification of multiple myeloma (MM) (8) , the present case did not have MGUS but symptomatic myeloma presenting with anemia and renal insufficiency. The criteria of International Staging System for myeloma (ISS) indicated that the clinical stage of this case was stage III, because serum β2 microglobulin of the patient was 8.4 μg/mL (>5.5 μg/mL) (9) . Although several reports have indicated that FDG-PET/CT is not able to detect a small lesion (10), most of the bone marrow in our patient demonstrated plasma cells. A possible explanation of the theoretical discrepancy between massive bone marrow involvement of myeloma cells and negative FDG-PET/CT findings is that IgD-lambda type myeloma cells may not be sufficiently metabolically active to form high uptake on FDG-PET/CT.
FDG, an analog of glucose, is used as a tracer of glucose metabolism. The mechanism by which FDG uptake arises in malignant cells is based on an increased number of glucose transporter proteins and upregulated levels of intracellular hexokinase and phosphofructokinase, which promote glycolysis. Therefore, tumors with low glycolytic activity are the major cause of false-negative findings. For example, bronchioloalveolar carcinoma, breast cancer, and carcinoid tumors have demonstrated false-negative findings on PET scans of not only primary sites but also metastatic lesions (11) (12) (13) .
Although massive bone marrow infiltration of myeloma cells (>45%) continued for a period of one year, the present patient had stable disease with MP therapy (Fig. 6 ). We considered that these findings may be related to the metabolic low activity of IgD type myeloma cells. To our knowledge, there is no other report describing FDG-PET or FDG-PET/ CT findings of IgD type MM. More studies are needed to clarify the utility of PET scan in the diagnosis of IgD type MM.
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